Post Parker Institute for Cancer Immunotherapy Scientists Present at ASCO 2018 on Gene Editing in Cell Therapy, Novel Checkpoint Inhibitor Combinations and Other Advances in Immuno-Oncology
Post Biomarkers May Predict Better Immunotherapy Treatment Outcomes for Certain Patients with Pancreatic Cancer
Post Parker Institute for Cancer Immunotherapy Researchers Present Findings on Pancreatic Cancer, Tumor Vaccines and CAR-T at 2017 Society for Immunotherapy of Cancer Annual Meeting
Post The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment